Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Onyx Frontier™ is a drug-eluting stent (DES) that’s engineered to deliver, different by design, and optimized for complex percutaneous coronary intervention (PCI).Download brochure
Onyx Frontier DES introduces an enhanced delivery system† and is designed to take the acute performance of Resolute Onyx™ DES even further.
Onyx Frontier DES features the same stent design differentiators that provide the conformability,1 visibility,2 fast healing,3 and size matrix you’ve come to rely on with Resolute Onyx DES.
Onyx Frontier DES is engineered to deliver,† featuring:
See the latest technology in action.
(Lower is better)
2-D track maximum force (GF scaled)
Onyx Frontier is the most deliverable DES yet.6
(Lower is better)
Average stent crossing profile (in)
Onyx Frontier is the only 3.0 mm DES with a crossing profile less than 1 mm.4
† Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx Frontier DES diameters.
Only Medtronic drug-eluting stents are made from a single wire, versus laser cutting, to enable a fluid range of motion for increased flexibility and the conformability needed for superior strut apposition.1
(Higher is better)
Average X-ray visibility index (%)
Zotarolimus drug and BioLinx™ polymer
The zotarolimus drug inhibits neointimal growth7 while the BioLinx biocompatible polymer — the only polymer specifically designed for a DES — promotes faster healing.3
Broad diameter range
Only Medtronic offers DES in 2.0 mm to 5.0 mm sizes, providing four platforms specifically designed to meet the needs of each vessel size.
|Stent length (mm)||
An exclusive set of design features and clinical data help ensure you have a reliable DES, even for your most challenging cases:
DAPT duration decisions are best made on an individual basis. Premature discontinuation or interruption of prescribed antiplatelet medication could result in a higher risk of ST, MI, or death.
(4.50–5.00 mm sizes)
Specifically designed with additional crowns and thicker struts (versus core sizes) to provide the radial strength needed for extra-large vessels.11
Expands from 4.50 mm up to 6.00 mm|| while maintaining structural integrity.
2.00-2.50 mm expand up to 3.50 mm||
Side branch access
Round struts create a smooth passage when accessing the side branch while lowering the propensity to catch.11
Rounded strut cross-section
1. Onyx Frontier DES‡
Square strut cross-section
1. SYNERGY™* DES
2. XIENCE™* DES
Chronic total occlusion (CTO)
The demonstrated deliverability, low crossing profile, and visibility of the Onyx DES platform make it ideal for CTOs.11
More CTO resources are available on Medtronic Academy.
Nonclinical testing has demonstrated that the Onyx Frontier stent is MR conditional for single and overlapping lengths up to 120 mm. A person with the Onyx Frontier DES implant may be safely scanned under the conditions found in the Onyx Frontier DES instructions for use. Failure to follow these conditions may result in injury.
View the data on one-month DAPT in HBR patients.
Browse a variety of PCI training and education resources.
™Third-party brands are trademarks of their respective owners.
Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx Frontier DES diameters.
Onyx Frontier DES has the same stent platform, with platinum-iridium core, as Resolute Onyx DES.
Clinical data evaluating Resolute Integrity™ and Resolute Onyx DES apply to Onyx Frontier DES.
Stents should not be expanded to a diameter beyond the maximum labeled diameter listed per the IFU. Post-dilation required for overexpansion.
Based on bench test data on file: third-party modeling and analysis. Data may not be indicative of clinical performance. Evaluated the following stent platforms: Resolute Onyx DES, Synergy DES, and Xience Alpine™* DES (Multi-Link 8™* BMS platform).
Based on bench test data on file at Medtronic. May not be indicative of clinical performance. Stents tested include Resolute Onyx DES, Synergy DES, XIENCE DES, and Orsiro DES.
Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.
Based on bench test data on file at Medtronic. May not be indicative of clinical performance. N = 5 DES of each tested: Onyx Frontier DES, Orsiro Mission DES, Resolute Onyx DES, XIENCE Skypoint DES, SYNERGY DES.
Based on bench test data on file at Medtronic. Compared to Resolute Onyx DES. May not be indicative of clinical performance.
Based on bench test data on file at Medtronic. May not be indicative of clinical performance. N = 7 of each DES: Onyx Frontier DES, Resolute Onyx DES, Orsiro Mission DES, XIENCE Sierra DES, XIENCE Skypoint DES, SYNERGY DES, SYNERGY XD DES.
Yeh RW, Silber S, Chen L, et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. February 2017;10(3):247-254.
Onyx Frontier DES IFU.
Kandzari DE, Kirtane AJ, Windecker S, et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv. November 2020;13:e009565.
Kandzari D, et al. Complex PCI with 1-month DAPT in HBR Patients. Presented at TCT 2020.
Based on bench test data on file at Medtronic. May not be indicative of clinical performance.
Cuellas C, et al. Use of a Zotarolimus-eluting stent for small vessel disease (DISCO 9 Study). Presented at PCR 2021.